---
id: esmo-pancreatic-cancer-2024
title: "ESMO 2024 Clinical Practice Guidelines: Pancreatic Cancer"
short_title: "ESMO Pancreatic Cancer 2024"

organization: European Society for Medical Oncology
collaborators: null
country: Global (Europe-led)
url: https://www.esmo.org/guidelines
doi: null
pmid: null
open_access: true

specialty: oncology
guideline_type: clinical-practice
evidence_system: ESMO GRADE
conditions:
  - pancreatic cancer
  - pancreatic adenocarcinoma
  - PDAC
tags:
  - Whipple
  - FOLFIRINOX
  - gemcitabine
  - neoadjuvant
  - CA 19-9

publication_date: 2024-04-01
previous_version_date: 2022-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-24
---

## Scope
2024 ESMO clinical practice guideline update on the diagnosis and management of pancreatic ductal adenocarcinoma (PDAC).

## Key Recommendations

### Diagnosis and Staging
- **CT Chest/Abdomen/Pelvis (pancreas protocol)**: Primary staging modality.
- **EUS with FNA/FNB**: For tissue diagnosis if not surgically resectable or for neoadjuvant planning.
- **CA 19-9**: Useful for prognosis and treatment monitoring.
- **Laparoscopy**: Consider for potentially resectable disease to rule out occult metastases.

### Resectable Disease
- **Surgery**: Pancreaticoduodenectomy (Whipple) for head tumors; distal pancreatectomy for body/tail.
- **Adjuvant Chemotherapy**: Modified FOLFIRINOX (if fit) or gemcitabine + capecitabine for 6 months. Improves survival.
- **Neoadjuvant Therapy**: Consider for borderline resectable tumors; may improve R0 resection rates.

### Borderline Resectable / Locally Advanced
- **Neoadjuvant Chemotherapy (± Chemoradiation)**: mFOLFIRINOX or gemcitabine-based regimens.
- Reassess for resectability after treatment.
- SBRT or chemoradiation may be considered for local control.

### Metastatic Disease
- **First-Line**: mFOLFIRINOX (fit patients) or gemcitabine + nab-paclitaxel.
- **Second-Line**: Switch regimen (e.g., gemcitabine-based if prior FOLFIRINOX, or vice versa). Consider liposomal irinotecan + 5-FU.
- **Molecular Testing**: BRCA1/2 mutations (platinum-sensitive, PARP inhibitor maintenance – olaparib), NTRK fusions, MSI-H (immunotherapy).

### Supportive Care
- Pain management, biliary stenting, pancreatic enzyme replacement, nutritional support.
